Area of research
Infectious Diseases · Hepatology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Hepatitis C virus research, Animal Virus Infections Studies, and SARS-CoV-2 detection and testing.
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
Safety and Immunogenicity of an mRNA-1273 Booster in Children
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
Homozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials
Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin